Intercept to Present at Upcoming Healthcare Conferences

NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer, will present at the following investor conferences:

  • RBC Capital Markets Healthcare Conference on February 26, 2014, at 11:00 a.m. ET, at The New York Palace hotel in New York, NY
  • Cowen & Company's 34th Annual Health Care Conference on March 3, 2014, at 12:00 p.m. ET, at The Boston Marriott Copley Place hotel in Boston, MA

Live and archived audio webcasts of the company's sessions will be available on the "Events" section of Intercept's investor website at

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma. For more information about Intercept, please visit the Company's website at:

CONTACT: For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: Investor inquiries: investors@interceptpharma.comSource:Intercept Pharmaceuticals, Inc.